Pharma Major Lupin announced that it has received final approval for its Doxycycline Hyclate Tablet USP, 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.'s Vibra-Tabs, 100 mg.

Lupin's Doxycycline Hyclate Tablet USP, 100 mg is the AB rated generic equivalent of Pfizer Inc.'s Vibra-Tabs, 100 mg. It is indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablet USP, 100 mg had US sales of USD 149.9 million (IMS MAT June 2017).

Shares of the company gained Rs 8.85, or 0.91%, to trade at Rs 977.00. The total volume of shares traded was 272,593 at the BSE (2.43 p.m., Monday).